Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
Landos Biopharma, a clinical-stage biopharmaceutical company (NASDAQ: LABP), announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The company has two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications, including the clinical stage program NX-13 for ulcerative colitis (UC). NX-13 is currently in a Phase 2 proof-of-concept trial (NEXUS: NCT05785715) to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The Company expects to report topline results in the fourth quarter of 2024.
Landos Biopharma's focus on immunometabolic pathways presents a novel approach in the treatment of autoimmune diseases, particularly ulcerative colitis (UC). The acceptance of six abstracts at the ECCO congress signifies a recognition within the scientific community of the potential impact of these therapies. The research on NLRX1 and PLXDC2 agonists, such as NX-13 and LABP-69, indicates a strategic pivot towards targeting the metabolic processes of immune cells to achieve therapeutic effects.
From a research perspective, the modulation of immunometabolism is a relatively new concept that could offer a dual mechanism of action—both immunological and metabolic. This could potentially lead to treatments with fewer side effects and improved patient compliance due to the oral administration of these therapies. The data presented on NX-13's impact on eosinophil infiltration and visceral hypersensitivity could suggest a broader applicability of this drug beyond UC, potentially addressing a range of inflammatory conditions.
The progress of NX-13 into a Phase 2 proof-of-concept trial is a critical step in the clinical development process. The trial's outcome will be pivotal in determining the drug's safety and efficacy profile. If positive, it could significantly enhance Landos Biopharma's market position and valuation, considering the high unmet need in UC treatment. However, it's important to note that the success of clinical trials is uncertain and the therapeutic market is highly competitive, with several established and emerging players.
Landos Biopharma's presentations at the ECCO congress could have implications for investor sentiment and the company's stock performance. The biopharmaceutical sector is highly sensitive to clinical trial data and regulatory milestones. Investors will be closely monitoring the outcomes of the NEXUS trial for NX-13, with topline results expected in the fourth quarter of 2024. Positive results could lead to an increase in stock value due to the anticipation of a new, potentially lucrative product entering the market.
Furthermore, the focus on immunometabolic modulators positions Landos at the forefront of a niche but expanding segment of the autoimmune disease market. The uniqueness of their approach could attract partnership opportunities, licensing deals, or even acquisition interest from larger pharmaceutical companies looking to diversify their portfolios with innovative therapies.
On the flip side, any setbacks in the clinical development of NX-13 could adversely affect the company's financial health and investor confidence. Given that Landos is a clinical-stage company, its financial stability is heavily reliant on the success of its pipeline products. The market will also consider the scalability of production and the potential market size for these therapies when assessing Landos' long-term viability.
Analyzing the financial implications of Landos Biopharma's research developments, the investment into novel immunometabolic pathways could offer substantial returns if NX-13 and other therapies in their pipeline succeed in clinical trials. The autoimmune disease treatment market is expected to grow and first-mover advantage with a new class of drugs could secure Landos a significant market share.
However, R&D in the biopharmaceutical industry is capital-intensive and the journey from discovery to market is fraught with regulatory hurdles and high attrition rates. Investors will be examining the company's burn rate and cash runway in relation to the anticipated milestones. Strategic alliances or future financing rounds may be necessary to sustain operations until a commercial product is available, assuming clinical success.
It is also important to consider the competitive landscape. The emergence of biosimilars and other novel therapies could pressure pricing and market penetration strategies for Landos' products. The company's valuation will reflect not only the potential of its pipeline but also its ability to navigate the market dynamics and secure a profitable position.
01/08/2024 - 08:00 AM
Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
“Immunometabolic targets work to restrict entry into the inflammatory cascade to restore and maintain homeostasis and are poised to be the next frontier in treating autoimmune diseases. We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species. Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos. “The broad range of innovative research by our scientists and esteemed collaborators underscores our commitment to leveraging immunometabolism to create safer and more effective treatments for inflammatory bowel diseases, particularly in ulcerative colitis.”
Landos has two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications, including the clinical stage program NX-13 for ulcerative colitis (UC).
Presentation Details
All six posters will be presented as part of the guided poster session taking place on Friday, February 23, 2024 from 12:40-13:40 CEST at Poster Exhibition Hall A. Title: The Immunometabolic Bimodal Mechanism of NLRX1 Agonist NX-13 in a Pig Model of Ulcerative ColitisPresenter: Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, BelgiumPoster number: P077
Title: Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in MicePresenter: Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, BelgiumPoster number: P086
Title: Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal InflammationPresenter: Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, BelgiumPoster number: P114
Title: Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel DiseasesPresenter : Prof. Silvio Danese, M.D., PhD; IRCCS San Raffaele Hospital, Vita-Salute San Raffaele UniversityPoster number: P144
Title: The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to HumanPresenter: Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, BelgiumPoster number: P571
Title: Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative ColitisPresenter: Prof. Britta Siegmund, M.D., PhD; Charité – Universitätsmedizin, BerlinPoster number: P739
NX-13 is currently in a Phase 2 proof-of-concept trial (NEXUS: NCT05785715 ) to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The Company expects to report topline results in the fourth quarter of 2024.
About Landos Biopharma
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. Our mission is to create safer and more effective oral treatments that address the therapeutic gap in the current treatment paradigm.
We have a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.
We are currently focused on advancing the clinical development of NX-13 in UC. We initiated the NEXUS Phase 2 proof-of-concept trial in April 2023 and expect to report topline results in the fourth quarter of 2024.
For more information, please visit www.landosbiopharma.com .
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the “Company”), including statements about the Company’s strategy, clinical development and regulatory plans for its product candidates and other statements containing the words “anticipate”, “plan”, “expect”, “may”, “will”, “could”, “believe”, “look forward”, “potential”, the negatives thereof, variations thereon and similar expressions, or any discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of current and future clinical trials, including the ongoing Phase 2 trial of NX-13, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates, our anticipated cash runway and other similar risks. Risks regarding the Company’s business are described in detail in its Securities and Exchange Commission (“SEC”) filings, including in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
Contacts
Rebecca Mosig, Vice President, Corporate Developmentir@landosbiopharma.com
Mike Moyermmoyer@lifesciadvisors.com
What is the company name that made the announcement about the six abstracts being accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)?
What is the ticker symbol of Landos Biopharma?
What is the Phase 2 proof-of-concept trial for NX-13?
What is the expected timeline for reporting topline results of the Phase 2 proof-of-concept trial for NX-13?
The fourth quarter of 2024
What is the clinical stage program for ulcerative colitis?
